구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Factor IX (FIX) |
Overview Company | CSL Behring |
Overview Modality | CGT |
Overview Target | Hemophilia B |
Overview Indication | Hemophilia B |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | AAV based gene therapy for hemophilia B pertains to dose-dependent vector-related i |
MoA Mechanism | targets the tissue factor pathway |
PK/PD Species | NHP, Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP |
PK/PD Experiment | Biodistribution |
Toxicology Species | NHP, Mouse |
Toxicology Animal (cat.) | Human, Mouse, NHP |
Toxicology Major finding | Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study.. We report efficacy and select safety outcomes of current factor prophylaxis of adults with moderately severe to severe hemophilia A (HA) or hemophilia B (HB) in a large, prospective, noninvestigational product study. This study established prospective efficacy da… |
Clinical Safety signal | Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study.. We report efficacy and select safety outcomes of current factor prophylaxis of adults with moderately severe to severe hemophilia A (HA) or hemophilia B (HB) in a large, prospective, noninvestigational product study. This study established prospective efficacy da… |
Clinical Selected reported efficacy | 5.2% |
Clinical Result source | ClinicalTrials.gov NCT02713204 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02713204 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Factor IX (FIX) |
Overview Company | CSL Behring |
Overview Modality | CGT |
Overview Target | Hemophilia B |
Overview Indication | Hemophilia B |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | AAV based gene therapy for hemophilia B pertains to dose-dependent vector-related i |
MoA Mechanism | targets the tissue factor pathway |
PK/PD Species | NHP, Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP |
PK/PD Experiment | Biodistribution |
Toxicology Species | NHP, Mouse |
Toxicology Animal (cat.) | Human, Mouse, NHP |
Toxicology Major finding | Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study.. We report efficacy and select safety outcomes of current factor prophylaxis of adults with moderately severe to severe hemophilia A (HA) or hemophilia B (HB) in a large, prospective, noninvestigational product study. This study established prospective efficacy da… |
Clinical Safety signal | Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study.. We report efficacy and select safety outcomes of current factor prophylaxis of adults with moderately severe to severe hemophilia A (HA) or hemophilia B (HB) in a large, prospective, noninvestigational product study. This study established prospective efficacy da… |
Clinical Selected reported efficacy | 5.2% |
Clinical Result source | ClinicalTrials.gov NCT02713204 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02713204 |
추천 비교
추천 비교